Balyasny Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Balyasny Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$873K	Buy	248,764 +180,726	+266%	+$578K	﹤0.01%	2136
2025 Q4	$186K	Sell	68,038 -22,586	-25%	-$52.3K	﹤0.01%	2898
2025 Q3	$197K	Sell	90,624 -1,417,158	-94%	-$3.35M	﹤0.01%	2728
2025 Q2	$2.59M	Buy	1,507,782 +1,297,841	+618%	+$3.23M	﹤0.01%	1598
2025 Q1	$699K	Sell	209,941 -2,609,858	-93%	-$13.5M	﹤0.01%	2149
2024 Q4	$20.9M	Sell	2,819,799 -1,652,777	-37%	-$15.3M	0.03%	646
2024 Q3	$42M	Sell	4,472,576 -67,984	-1%	-$644K	0.07%	365
2024 Q2	$36.4M	Buy	4,540,560 +3,339,696	+278%	+$35.8M	0.06%	388
2024 Q1	$17.8M	Sell	1,200,864 -2,725,295	-69%	-$31.7M	0.03%	666
2023 Q4	$31.9M	Sell	3,926,159 -550,677	-12%	-$2.88M	0.06%	423
2023 Q3	$20.4M	Buy	4,476,836 +2,937,029	+191%	+$19.2M	0.04%	564
2023 Q2	$10.8M	Sell	1,539,807 -1,195,779	-44%	-$8.56M	0.02%	736
2023 Q1	$16.7M	Buy	2,735,586 +2,731,832	+72,771%	+$18.8M	0.04%	583
2022 Q4	$24K	Sell	3,754 -1,739,778	-100%	-$13.6M	﹤0.01%	2459
2022 Q3	$16.7M	Buy	1,743,532 +233,743	+15%	+$2.7M	0.05%	490
2022 Q2	$16.7M	Buy	1,509,789 +415,765	+38%	+$5.45M	0.05%	484
2022 Q1	$18.2M	Buy	1,094,024 +297,189	+37%	+$4.6M	0.06%	453
2021 Q4	$15.2M	Sell	796,835 -166,625	-17%	-$3.67M	0.05%	510
2021 Q3	$23.8M	Buy	963,460 +354,336	+58%	+$8.35M	0.1%	285
2021 Q2	$15.8M	Buy	609,124 +441,812	+264%	+$11.5M	0.08%	361
2021 Q1	$5.3M	Buy	+167,312	New	+$6.94M	0.03%	678
2020 Q4	–	Sell	-437,864	Closed	-$17.4M	–	1513
2020 Q3	$14.4M	Buy	+437,864	New	+$13.4M	0.11%	279
2020 Q2	–	Sell	-355,779	Closed	-$11.7M	–	1306
2020 Q1	$10.7M	Buy	+355,779	New	+$9.43M	0.13%	221
2019 Q2	–	Sell	-38,011	Closed	-$361K	–	1593
2019 Q1	$361K	Sell	38,011 -13,104	-26%	-$127K	﹤0.01%	1265
2018 Q4	$452K	Sell	51,115 -93,172	-65%	-$899K	﹤0.01%	1121
2018 Q3	$1.62M	Buy	144,287 +109,210	+311%	+$1.55M	0.01%	1047
2018 Q2	$449K	Buy	+35,077	New	+$513K	﹤0.01%	1380

Other funds holding IOVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Balyasny Asset Management's IOVA Position: Q1 2026 in Review

Balyasny Asset Management increased its Iovance Biotherapeutics (IOVA) stake by 266% in Q1 2026, buying an estimated $578K and bringing the position to 248,764 shares worth $873K. The position accounts for ﹤0.01% of the portfolio, ranked #2136.

Balyasny Asset Management first reported a position in IOVA in Q2 2018 and has held it in 27 quarters since. The position peaked at $42M in Q3 2024. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

Balyasny Asset Management held 248,764 shares of Iovance Biotherapeutics worth $873K as of Q1 2026.
Balyasny Asset Management bought 180,726 Iovance Biotherapeutics shares in Q1 2026, an estimated $578K.
Iovance Biotherapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2136 holding.
Balyasny Asset Management first reported a position in Iovance Biotherapeutics in Q2 2018 and has held it in 27 quarters since.
Balyasny Asset Management's Iovance Biotherapeutics position peaked at $42M in Q3 2024.
285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.